EUVIMEDEUVIMED entdecken
ÜbersichtsarbeitOpen Access · CC BY-NC-ND 4.0

Combined Cancer Immunotheranostic Nanomedicines: Delivery Technologies and Therapeutic Outcomes

Tasneem A Nasser, Rawan Adel, Abdelrahman Badr, Mohamed Teleb, Adnan A Bekhit, Kadria A Elkhodairy, Ahmed S Abdelhamid, Ahmed O Elzoghby iD

ACS Omega · 07.02.2023 · 8 (5) · 4491-4507

DOI: 10.1021/acsomega.2c05986 ↗

Kurz gefasst

Übersichtsarbeit in der Zeitschrift ACS Omega, online erschienen am 27.01.2023. Verfasst von Tasneem A Nasser und 7 weiteren Autor:innen. Beteiligte Einrichtung: Cancer Nanotechnology Research Laboratory (CNRL), Faculty of Pharmacy, Alexandria University, Alexandria 21521, Egypt. Die Arbeit wurde bisher 12-mal zitiert (Crossref) und nennt 70 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0).

AbstractBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Cancer is among the main causes of mortality all over the world. The delayed diagnosis is directly related to the decrease in survival rate. The use of immunotherapy has dramatically changed the treatment outcomes of different types of cancers. However, many patients still do not respond to immunotherapies, and many also suffer from severe immune-related side effects. Recent advances in the fields of nanomedicine bioengineering and in particular imaging offered new approaches which can enhance not only the safety but also the efficacy of immunotherapy. Theranostics has showed great progress as a branch of medicine which integrates both diagnosis and therapy in a single system. The outcomes from animal studies demonstrated an improvement in the diagnostic and immunotherapeutic potential of nanoparticles within the theranostic framework. Herein, we discuss the most recent developments in the application of nanotheranostics for combining tumor imaging and cancer immunotherapies.

Autor:innen und Institutionen

  • Cancer Nanotechnology Research Laboratory (CNRL), Faculty of Pharmacy, Alexandria University, Alexandria 21521, Egypt.
  • Department of Pharmaceutical Chemistry, Faculty of Pharmacy, Alexandria University, Alexandria 5372066, Egypt.
  • Department of Industrial Pharmacy, Faculty of Pharmacy, Alexandria University, Alexandria 5372066, Egypt.
  • Division of Engineering in Medicine, Department of Medicine, Brigham and Women's Hospital, Harvard Medical School, Boston, Massachusetts 02115, United States.

ORCID-Profile: Ahmed O Elzoghby

Zitieren

APA

Nasser, T. A., Adel, R., Badr, A., Teleb, M., Bekhit, A. A., Elkhodairy, K. A., Abdelhamid, A. S., & Elzoghby, A. O. (2023). Combined Cancer Immunotheranostic Nanomedicines: Delivery Technologies and Therapeutic Outcomes. ACS Omega, 8(5), 4491-4507. https://doi.org/10.1021/acsomega.2c05986

Vancouver

Nasser TA, Adel R, Badr A, Teleb M, Bekhit AA, Elkhodairy KA, et al. Combined Cancer Immunotheranostic Nanomedicines: Delivery Technologies and Therapeutic Outcomes. ACS Omega. 2023;8(5):4491-4507. doi:10.1021/acsomega.2c05986

BibTeX
@article{Nasser2023,
  author = {Nasser, Tasneem A and Adel, Rawan and Badr, Abdelrahman and Teleb, Mohamed and Bekhit, Adnan A and Elkhodairy, Kadria A and Abdelhamid, Ahmed S and Elzoghby, Ahmed O},
  title = {Combined Cancer Immunotheranostic Nanomedicines: Delivery Technologies and Therapeutic Outcomes},
  journal = {ACS Omega},
  year = {2023},
  volume = {8},
  number = {5},
  pages = {4491--4507},
  doi = {10.1021/acsomega.2c05986}
}
Kostenlos starten →